Clinical Trial

Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke

Study acronym: FUSE-IT
Recruiting
View on ClinicalTrials.gov →
Summary
Endovascular thrombectomy (EVT) is the standard of care for acute ischemic stroke (AIS) caused by a large vessel occlusion. Successful recanalization is one of the most important factors for a good patient outcome, especially when obtained within 30 minutes from groin puncture, and the procedural success-rate reaches above 90% at treating centers of excellence. There are however a portion of cases where recanalization is not achieved, which in some cases are attributed to difficult arterial anatomy affecting the ability to catheterize the precerebral target vessel. In the latest angiography platforms, 3D reconstructions of the aortic, cervical and intracranial arteries from the preprocedural CT angiography can be fused with periprocedural 2D digital subtraction angiography and/or fluoroscopy images, so called 2D/3D Fusion imaging. The preparation steps can be done before patient arrival to the angiography suite and the image fusion can be done in less than a minute during patient preparation. Previous observational studies have shown that the use of fusion imaging during EVT procedures may decrease failed target vessel access and increase procedural success rate and first-pass recanalization rate, without prolonging the procedure. The purpose of this study is to assess the use of fusion imaging in EVT procedures and its effect on target vessel access, recanalization success-rate and procedure times.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-08; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2026-03-02
Trial Details
NCT Number NCT06975696
Lead Sponsor Region Skane
Collaborators: Örebro Läns Landsting, Helsinki University Central Hospital, University of Turku, Lund University, Insel Gruppe AG, University Hospital Bern
Conditions Stroke Acute
Enrollment 300 participants
Start Date 2026-03-02
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-04